Abstracts tagged "Pediatric rheumatology"

Abstract Number: 0804 • ACR Convergence 2023
Mutated NOD2 Controls IL-2 Production in Blau Syndrome Patients and Mice
Leah M. Huey¹, Emily Vance¹, Holly L. Rosenzweig², Bryce Binstadt³ and Ruth J. Napier², ¹Oregon Health & Science University, Portland, OR, ²Oregon Health & Science University, VA Portland Health Care System, Portland, OR, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Microbial sensing molecule nucleotide-binding oligomerization-domain containing protein 2 (NOD2) is expressed by CD4+ T cells and plays a novel T cell-intrinsic role within CD4+…
Abstract Number: 1226 • ACR Convergence 2023
Examining the Relationship Between Socioenvironmental Factors and Cognitive Functioning in Youth with Childhood-Onset Systemic Lupus Erythematosus
Ashley Danguecan¹, Ibrahim Mohamed², Sarah Mossad¹, Tala El Tal³, Adrienne Davis¹, Asha Jeyanathan¹, Sona Sandhu¹, Lawrence Ng¹, Paris Moaf¹, Deborah Levy¹, Linda Hiraki¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Brampton, ON, Canada, ³Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Problems with cognitive functioning are common in childhood-onset systemic lupus erythematosus (cSLE); these may be attributed to many factors including underlying brain inflammation. Socioenvironmental…
Abstract Number: 1243 • ACR Convergence 2023
Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study
Ryan Mitacek, Qiong Liu, Linda Wagner-Weiner, Shireen Hashmat and Anthony Chang, University of Chicago, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…
Abstract Number: 1624 • ACR Convergence 2023
Racial Disparities Impact Achieving LLDAS and Glucocorticoid Use in Pediatric Lupus: A CARRA Registry Study
William Soulsby¹, Rebecca Olveda¹, Jie He², Laura Berbert², Edie Weller², Kamil Barbour³, Kurt Greenlund³, Laura Schanberg⁴, Emily von scheven¹, Aimee Hersh⁵, Mary Beth Son⁶, Joyce Chang² and Andrea Knight⁷, ¹University of California San Francisco, San Francisco, CA, ²Boston Children's Hospital, Boston, MA, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴Duke University School of Medicine, Durham, NC, ⁵University of Utah, Salt Lake City, UT, ⁶Division of Immunology, Boston Children's Hospital, Boston, MA, ⁷The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Social determinants of health (SDoH) contribute to disparate outcomes in both adult and pediatric systemic lupus erythematosus (pSLE), including length of hospitalization, mortality, and…
Abstract Number: 2044 • ACR Convergence 2023
Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population
Alhanouf Alsaleem, Sulaiman Al-Mayouf and Shahad Alansari, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Background/Purpose: IFN-mediated diseases are mendelian innate immunodysregulatory disorders that present early in life with fevers, sterile organ inflammation, and a high type-I IFN-response gene signature…
Abstract Number: 2314 • ACR Convergence 2023
Comparison of Disease Severity and Outcomes in Adolescent-Onset and Young Adult-Onset Systemic Lupus Erythematosus
Emma Materne¹, Baijun Zhou¹, Hyon K. Choi², Yuqing Zhang³ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Adolescent-onset SLE is associated with more severe disease than adult-onset SLE, but young adults may also experience adverse outcomes. We sought to compare disease…
Abstract Number: 0101 • ACR Convergence 2023
Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome
Elizabeth Sloan¹, Katarina Kmetova², NaveenKumar K. Somanathapura², Lyndsay Kluge², Emily Chong², Claire Hoy², Srilakshmi Yalavarthi², Jacqueline Madison², Cyrus Sarosh², Lynnette Walters³, Jeanine Baisch⁴, Jessica Turnier², Virginia Pascual⁴, Tracey Wright¹, Jason Knight², Ayesha Zia¹ and Yu Zuo², ¹UT Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³Scottish Rite Hospital for Children, Dallas, TX, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: While classification criteria for pediatric APS are not yet available, recent research suggests pediatric APS patients are unique, and many present with extra-criteria manifestations…
Abstract Number: 0364 • ACR Convergence 2023
Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis
Adam Mayer¹, Timothy G. Brandon², Pamela F. Weiss³ and on behalf of the JAXSPERT members², ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The extent to which heterogeneity exists in youth with axial disease and juvenile spondyloarthritis (JSpA) is unclear. In a cross-sectional sample of patients classified…
Abstract Number: 0830 • ACR Convergence 2023
The Upregulation of MAP Kinase Pathway Genes Is Associated with Poor Treatment Response to Tofacitinib in Polyarticular Course Juvenile Idiopathic Arthritis
Esraa Eloseily¹, Alex Pickering², Sanjeev Dhakal¹, Hermine Brunner³, Sherry Thornton⁴ and Alexei Grom¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Harvard Medical School Department of Biomedical Informatics, Boston, MA, ³Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Despite significant progress in understanding the pathophysiology of Juvenile Idiopathic Arthritis (JIA), the availability of tools to accurately predict treatment response remains limited. Our…
Abstract Number: 1227 • ACR Convergence 2023
Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Jordan Roberts¹, Anna Faino², Mersine Bryan¹, Jonathan Cogen¹ and Esi Morgan¹, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children’s Research Institute, Seattle, WA
Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…
Abstract Number: 1244 • ACR Convergence 2023
Characterizing Lupus in African American Children in Southern United States
Anita Dhanrajani¹, Taylor Long², Spencer Hagwood², Cynthia Karlson² and Cali Foreman², ¹University of Mississippi Medical Center, New Orleans, LA, ²University of Mississippi Medical Center, Jackson, MS
Background/Purpose: African-American (AA) ethnicity is a known predisposing factor for childhood onset systemic lupus erythematosus (cSLE) and a predictor of poor outcomes. In addition to…
Abstract Number: 1625 • ACR Convergence 2023
Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning
santiago arciniegas¹, Matthias W. Wagner², Logi Vidarsson², Birgit Ertl-Wagner², Tala El Tal³, Asha Jeyanathan², Lawrence Ng², Linda Hiraki², Deborah Levy², George M. Ibrahim² and Andrea Knight², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Childhood-onset SLE (cSLE) is characterised by a higher frequency of nervous system involvement, known…
Abstract Number: 2046 • ACR Convergence 2023
Implementation of an Automated Transition Readiness Assessment in a Pediatric Rheumatology Clinic
Elizabeth Murray¹, Melissa Argraves¹, Alysha Taxter², Kelly Wise³, Paul Jensen⁴, Alana Goldstein-Leever¹, Bethanne Thomas¹, Alexa Scott¹, Jonnie Lee Hughes¹, James Gallup¹, Diana Sumano Vicente¹, Stacy Ardoin¹ and Vidya Sivaraman¹, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's, Columbus, OH, ³Nationwide Children's Hospital, Hilliard, OH, ⁴Intermountain Southwest Rheumatology Associates, St. George, UT
Background/Purpose: Many pediatric patients are inadequately prepared for the transition from pediatric to adult subspecialty healthcare, and patients who fail to transition successfully are more…
Abstract Number: 2458 • ACR Convergence 2023
The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center
Emily Beil¹, Eyal Muscal², Abiodun Oluyomi³, Omar Rosales³, Danielle Guffey⁴, Marietta DeGuzman¹, Cagri Yildirim-Toruner⁵, Andrea Ramirez³ and Erin Peckham-Gregory³, ¹Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ²Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, ⁵Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The prevalence of childhood-onset SLE (cSLE) differs by racial/ethnic group. Yet, the role of social determinants of health (SDoH) in disease severity is not…
Abstract Number: 0182 • ACR Convergence 2023
Impact of Neighborhood-level Child Opportunity on Disease Activity in Children with Lupus
Joyce Chang¹, Gabrielle Alonzi¹, Emily Smitherman², Pooja Patel³, Gabrielle Morgan⁴, Livie Huie⁵, Karen Costenbader⁶ and Mary Beth Son⁷, ¹Boston Children's Hospital, Boston, MA, ²University of Alabama at Birmingham, Birmingham, AL, ³Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Alabama at Birmingham, Gardendale, AL, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Racial disparities in outcomes of pediatric SLE (pSLE) have persisted over time. This may be mediated by structural racism, which segregates children belonging to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].